Nanotech Revives a Cancer Drug: related news

Nanotech Revives a Cancer Drug

Special delivery: This blood-vessel cell--the same type of cell that feeds spreading tumors--has absorbed a newly formulated cancer drug. In this fluorescence image, the cell’s structural elements are labeled red, the nucleus is labeled blue, and a cancer drug encased in a polymer envelope is labeled green.

Nanotech Revives a Cancer Drug

In the 1990s, a cancer drug called TNP-470 dramatically increased life span for some patients and led to complete cancer regression in others. But when neurotoxicity was detected in some patients, clinical trials were halted. This is a common problem: many drugs that show great promise in the lab fail in clinical trials due to unforeseen toxicity. Nanomedicine, however, promises a way to make safer, more effective versions of such drugs. Researchers at Children's Hospital Boston have created and tested in mice a safer version of TNP-470.

Sngle-walled carbon nanotubes used as cancer drug delivery vehicles

Add our medical news to StumbleUpon - Sngle-walled carbon nanotubes used as cancer drug delivery vehicles Add our medical news to Facebook - Sngle-walled carbon nanotubes used as cancer drug delivery vehicles

Nanotech Sciences Corp. Announces Private Placement

Nanotech Sciences Corp. ("Nanotech") (TSX VENTURE:NAN.P) is pleased to announce further advancement of its "Qualifying Transaction" in accordance with TSX Venture Exchange (the "Exchange") Policy 2.4, with Natcore Technology Inc. ("Natcore"), previously announced on June 19, 2008. Subject to completion of the Qualifying Transaction, Nanotech will raise up to $4,000,000 by way of concurrent brokered and non-brokered private placements (collectively, the "Offering") of units ("Units") at $0.40 per Unit, each Unit comprising one common share and one share purchase warrant ("Warrants"), where each Warrant is exercisable for a period of two years from closing to purchase one additional common share of Nanotech at a price of $0.75 per share. The Warrants will be subject to forcible conversion within 30 days of delivery of a notice from Nanotech

Cancer Resistance Technique Moves To Human Trials

TaeKwonDood tips us to news that a new cancer resistance treatment is going into clinical trials after being quite successful at eradicating cancer in mice. Researchers discovered that certain white blood cells called granulocytes from cancer-immune mice were able to cure cancer in other mice. Now, doctors are putting out the call for healthy granulocyte donors in order to test how well it works on humans. The article quotes lead researcher Zheng Cui saying, "In mice, we've been able to eradicate even highly aggressive forms of malignancy with extremely large tumors. Hopefully, we will see the same results in humans. Our laboratory studies indicate that this cancer-fighting ability is even stronger in healthy humans."

Applied Nanotech Holdings, Inc. (Formerly Nano-Proprietary, Inc.) Announces New Trading Symbol

AUSTIN, TX, Jul 01 (MARKET WIRE) -- Applied Nanotech Holdings, Inc. (OTCBB: APNT) announced that its new trading symbol is effective with the start of trading today. The new symbol is required as a result of the change in the Company's name. This new symbol was assigned by NASDAQ, operator of the OTC Bulletin Board. Shareholders that hold shares in certificate form do not need to take any action. Existing certificates with the name Nano-Proprietary, Inc. on them will still represent ownership in Applied Nanotech Holdings, Inc. ABOUT APPLIED NANOTECH HOLDINGS, INC. Applied Nanotech Holdings, Inc., formerly Nano-Proprietary, Inc., is a holding company consisting of two wholly owned operating subsidiaries. Applied Nanotech, Inc. is a premier research and commercialization organization dedicated to developing applications for nanotechnology w

Cancer Drug Resistance: Enzyme Expression Levels Correlated With Chemotherapy Drug Response

Why do cancer patients develop resistance to chemotherapy drugs, sometimes abruptly, after a period in which the drugs seem to be working well to reduce tumors or hold them in check? Although largely a mystery to scientists, the result when this occurs is all too familiar: patients relapse and in many cases die when their cancers become resistant.

Patent bid sparks cancer-test price fears

A decision by Genetic Technologies could make breast cancer examinations more expensive, according to Cancer Australia. Genetic holds the Australian and New Zealand patent licences for a test that detects mutations in breast cancer genes, and recently announced plans to use its patent rights to conduct all future testing itself. Women with the defective gene have an 85 per cent change of contracting the disease, against a community-wide average of around nine per cent. Cancer Council Australia CEO, Ian Olver, said allowing genes to be patented could be problematic in the long term and could compromise the Human Genome Project

Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis

(PHILADELPHIA) Scientists at the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia have made a key discovery about the mechanism of breast cancer metastasis, the process by which cancer spreads. Focusing on a gene dubbed "Dachshund," or DACH1, they are beginning to pinpoint new therapeutic targets to halt the spread of cancer.

Olympic Gold Medalist Inspires Cancer Patients Through Blog

BEIJING, August 18, 2008 /PRNewswire/ -- Dick Fosbury, gold medalist from the 1968 Olympic Games in Mexico City and innovator of the high jump technique dubbed the "Fosbury Flop," which revolutionized the sport and is now considered its standard, was stricken by cancer lymphoma in March. After undergoing surgery, radiation and chemotherapy treatment at the Cancer Center, the State of New Mexico's Official Cancer Center based on the UNM campus in Albuquerque, NM, Fosbury is currently attending the 2008 Olympics Games in Beijing to celebrate the 40th anniversary of the "Fosbury Flop" and inspire cancer patients throughout the world.

Olympic Gold Medalist Inspires Cancer Patients Through Blog

BEIJING, Aug. 18 /PRNewswire/ -- Dick Fosbury, gold medalist from the 1968 Olympic Games in Mexico City and innovator of the high jump technique dubbed the "Fosbury Flop," which revolutionized the sport and is now considered its standard, was stricken by cancer lymphoma in March. After undergoing surgery, radiation and chemotherapy treatment at the University of New Mexico Cancer Center, the State of New Mexico's Official Cancer Center based on the UNM campus in Albuquerque, NM, Fosbury is currently attending the 2008 Olympics Games in Beijing to celebrate the 40th anniversary of the "Fosbury Flop" and inspire cancer patients throughout the world.

Olympic Gold Medalist Inspires Cancer Patients Through Blog

BEIJING, Aug 18, 2008 /PRNewswire via COMTEX/ -- Dick Fosbury, gold medalist from the 1968 Olympic Games in Mexico City and innovator of the high jump technique dubbed the "Fosbury Flop," which revolutionized the sport and is now considered its standard, was stricken by cancer lymphoma in March. After undergoing surgery, radiation and chemotherapy treatment at the University of New Mexico Cancer Center, the State of New Mexico's Official Cancer Center based on the UNM campus in Albuquerque, NM, Fosbury is currently attending the 2008 Olympics Games in Beijing to celebrate the 40th anniversary of the "Fosbury Flop" and inspire cancer patients throughout the world.

LegalView Informs Mesothelioma Blog Readers of A New Clinical Trial Available for Victims of Asbestos-Induced Lung Cancer

blog on an opportunity for pleural mesothelioma cancer victims to participate in a clinical trial being conducted at the Mesothelioma Center at New York-Presbyterian Hospital and Columbia University Medical Center. The clinical trial hopes to improve surgical and radiation treatments for patients of pleural mesothelioma cancer. Currently, the most common treatment for patients of the asbestos-induced cancer is removal of the victim's lung. Individuals who suffer from pleural mesothelioma or any other form of mesothelioma cancer are advised to speak with an experienced

LSU Health Sciences Center Inventor Awarded Patent for New Procedure to Detect Cancer Spread

NEW ORLEANS, June 24 (AScribe Newswire) -- Eugene A. Woltering, MD, FACS, The James D. Rives Professor of Surgery and Chief of the Sections of Surgical Oncology & Endocrine Surgery at LSU Health Sciences Center New Orleans, has been awarded a US Patent for a one-step method to rapidly identify "sentinel nodes;" the lymph nodes most likely to contain early metastasis from a primary cancer. Preliminary research indicates that the procedure which consists of injection of a radiolabeled dye around a cancer can identify sentinel nodes that receive lymphatic drainage from the tumor within 10 minutes. Dr. Woltering's patent is based on linking a radioactive iodine molecule to the blue dye commonly used in these sentinel node procedures. One of the major ways to determining the prognosis of a cancer involves determining whether the cancer has met

LegalView Informs Mesothelioma Blog Readers of A New Clinical Trial Available for Victims of Asbestos-Induced Lung Cancer

(EMAILWIRE.COM, July 08, 2008 ) Denver, CO - LegalView.com, the number one legal resource on the Web, offered information through its mesothelioma information (http://mesothelioma.legalview.com/blog ) blog on an opportunity for pleural mesothelioma cancer victims to participate in a clinical trial being conducted at the Mesothelioma Center at New York-Presbyterian Hospital and Columbia University Medical Center. The clinical trial hopes to improve surgical and radiation treatments for patients of pleural mesothelioma cancer. Currently, the most common treatment for patients of the asbestos-induced cancer is removal of the victim's lung. Individuals who suffer from pleural mesothelioma or any other form of mesothelioma cancer are advised to speak with an experienced mesothelioma lawyer (http://mesothelioma.

Nanotech Northern Europe Hosts World's First Truly Global Panel on Public-Sector Nanotech Funding

Home > Press > Nanotech Northern Europe Hosts World’s First Truly Global Panel on Public-Sector Nanotech Funding

Nanotech Northern Europe Hosts World's First Truly Global Panel on Public-Sector Nanotech Funding

Home arrow Sports arrow Nanotech Northern Europe Hosts World’s First Truly Global Panel on Public-Sector Nanotech Funding

Experts describe promise of nanotech for cancer detection, more

Speakers from MIT and other institutions described the promise of nanotechnology to help diagnose, treat and monitor cancer at the annual symposium hosted by the David H. Koch Institute for Integrative Cancer Research at MIT on Friday, June 27.

NANOTECH ENTERTAINMENT ANNOUNCES INTERNATIONAL SALES REPRESENTATION BY TOO FUN

SAN JOSE, Calif.– June 24, 2008– NANOTECH ENTERTAINMENT, the world's most innovative gaming technology company, today announced that it has entered into an exclusive sales representation agreement with Too Fun, Inc., a worldwide leader in coin-op sales. Under the agreement, Too Fun will represent the entire NanoTech coin-op product line worldwide.“The opportunity to partner with Mehdi and the Too Fun team is an excellent opportunity for us. They are well recognized in the world coin-op market, and have vast penetration into many up and coming markets.� stated Robert DeKett, founder and CEO of NanoTech.

Low-Carb Blog Reader Asking For 'Relay For Life' Cancer Drive Help

Cancer more than any other disease has ripped through families, communities, churches, organizations, and cities all across America like no other disease I know. Just two weeks ago, endometrial cancer took the wife of national radio talk show host Mike Gallagher after months of battling it with chemotherapy and just one year ago my friend and former minister of music Steve Dyar went home to be with the Lord after esophageal cancer overtook his body.

Drug Halts Decline In Alzheimer's Patients

ljw1004 writes "Alzheimer's researchers are divided on whether the disease is caused by 'beta amyloid' (a peptide found in Alzheimer brains) or by 'tau protein' (normally used for cellular scaffolding, but can aggregate out of control and destroy neurons). Today in Chicago a new drug has been announced that stops tau aggregation and appears to have halted Alzheimer's-related decline in 300 clinical trial patients. The drug is known as 'rember.' Do you have friends or family who appear to be on the road to dementia? Here is an online questionnaire, part of one used in the clinical trial to diagnose dementia. (Disclosure: I made the online questionnaire, and my father is one of the scientists behind the drug.)"

DestinationRx Launches Drug Trends Today Blog

LOS ANGELES & CHICAGO - (Business Wire) DestinationRx today announced the launch of its new blog site, www.drugtrendstoday.com, which will serve as a vehicle for sharing data and trends related to the prescription drug industry. As a leader in drug comparison and purchasing technology, DestinationRx is in a unique position to provide readers with valuable and relevant information on the ever-changing drug market.

DestinationRx Launches Drug Trends Today Blog

LOS ANGELES & CHICAGO--(BUSINESS WIRE)--Jul 17, 2008 - DestinationRx today announced the launch of its new blog site, www.drugtrendstoday.com, which will serve as a vehicle for sharing data and trends related to the prescription drug industry. As a leader in drug comparison and purchasing technology, DestinationRx is in a unique position to provide readers with valuable and relevant information on the ever-changing drug market.

DestinationRx Launches Drug Trends Today Blog

LOS ANGELES & CHICAGO--(BUSINESS WIRE)--July 17, 2008--DestinationRx today announced the launch of its new blog site, www.drugtrendstoday.com, which will serve as a vehicle for sharing data and trends related to the prescription drug industry. As a leader in drug comparison and purchasing technology, DestinationRx is in a unique position to provide readers with valuable and relevant information on the ever-changing drug market.

Search took 0.13 seconds.